Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morphine + ibuprofen is a combination of two active pharmaceutical ingredients used together for the management of moderate to severe pain. Morphine is an opioid analgesic that acts primarily as an agonist at mu-opioid receptors in the central nervous system, leading to inhibition of nociceptive (pain) signaling and modulation of pain perception. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which results in decreased inflammation, pain, and fever. The combination aims to provide enhanced analgesia through complementary mechanisms—opioid receptor agonism and peripheral anti-inflammatory action—potentially allowing for lower doses of each component compared to monotherapy. This can improve pain control while potentially reducing opioid requirements and associated side effects[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + ibuprofen.